The established conditions include the following: patients under 65 years old no hepatic comorbidity and treatment prescribed by physicians with experience in arthrosis therapies. Regarding this point, we feel it important to review the latest EMA recommendations, which allow, under very specific conditions, the use of diacerein in treating arthrosis. Your letter provides us with complementary information regarding the registration status of diacerein in Europe, specifically as related to the recommended suspension of marketing authorization made by the European Medicines Agency (EMA), as a result of patient cases of severe diarrhea and hepatic alterations.
Thank you for your letter published in Medwave regarding our article titled “Is diacerein an alternative for osteoarthritis treatment?”.
0 kommentar(er)
